Abbott Laboratories, (ABT)’s stock has risen by 18.6% from average 12-month price target of $94.32 expected by the analysts. The price of the stock ended October 02, 2019 trading at $79.53 which saw downtrend of 9.95% since the beginning of 2019. For most investors, the -2.82% rally in the share price could have prompted them tosell the stock, but doing that would be a mistake as it would be taking into consideration only the short-term performance of the stock. Most analysts believed that the stock has the potential to rise by 24.48% or more. For Abbott Laboratories to record further gainanalysts believe that the company has to hit $99 price target. The high price target for ABT for next 12 months currently stands at $99. This means that the highest 12 months price target is 24.48% above its last closing price. The median price target for the stock over the next 12 months is $94, which means that it could rise by 18.19% from its current position. Despite that, some analysts believe that it won’t perform excellent, setting a lower price target of $90 for the stock which means it could rise by 13.16%.
A look at the ABT stock today shows that it has gained 7.3% of its value over the past one year, which has led to some investors becoming excited about the short-term performance of Abbott Laboratories (NYSE:ABT). If we turn to the stock analysts in general, they revealed that most of them are still bullish about the chances of the shares. The consensus rating from analysts for Abbott Laboratories (ABT) is 1.7 which is a buy rating. Over the past week, the stock has been rated as a Buy 13 times while it has been rated as a Hold 1 times. The 52-week high price for ABT is $88.76 which is attained on July 23 while its 52-week low currently stands at $65.44 and was reached on December 24. At the moment, the stock is trading $0.07 above its YTD moving average set at $79.46.
Moving on, Abbott Laboratories (ABT) last released its earnings for the June 2019 quarter of the fiscal year. The company performed decently over the past three months, with its earnings up 95% year-over-year at $0.82. The company brought a surprise of 2 as analysts were predicting $0.8 per share. The revenue generated by Abbott Laboratories in the June 2019 quarter surged by 3% to reach $7.98 billion. This is highcompared to the $7.77 billion it recorded in the same quarter last year. To see what traders should watch in its September 2019 financial results, analysts have consensus earnings per share of $0.84 which is higherthan the $0.75 recorded in the same quarter a year ago. Over the next 12 months, the earnings per share are expected to move by 11.62%. If it achieves that, then the company firmly believes that its long-term annual earnings growth rate target set at 11.81 % could be achieved. The company has also recorded a revenue of $30.94 billion over the past 12 months.
In order to determine if the stock is worthy of your patience, you should know that Abbott Laboratories (NYSE:ABT) is now trading at 48.38X the earnings per share recorded over the past 12 months. This is an uptrend compared to the readings of the sector which is 30.42X while the industry average stands at 27.91X. The most popular way to value a stock is to look at its historic Price-to-Earnings (P/E) ratio with the help of its earnings report over the past 12 months. Abbott Laboratories was able to achieve an EPS of $1.64 during the last four quarters. The P/E ratio is widely known due to the fact that it is widely used, simple, effective, and, tautologically.
On Wednesday, October 02 of 2019, the 14-day Absolute ATR (Average True Range) for ABT moved by $1.75. Over the past seven days, the stock’s average daily volatility stood at 2.76%. A stock with a low volatility is usually a good one as it means that investors are very confident in the stock. Abbott Laboratories’s trading volume has recently moved to 5.55 million, which is compared with the average daily volume of 4.5 million shares.
The daily chart for ABT, points out that the company has recorded 0.04% gains over the past six months. However, it is still 21.53% higher than its most recent low trading price. The performance of the stock over the past five days shows that it is down -4.02% though it is -4.95% below its three-week moving average. It is worthy to know that price action is not always clear. There are times when a stock will undergo some negatives, trade erratically within some range or even act very unpredictable. When that happens, then making use of moving averages makes the pattern clearer for traders. Comparing to 50-day SMA, the price of the stock has dropped by -6.17% while it is up 0.78% against the 200-day SMA. This is usually seen as the last support line for a stock, as a move downward could signal a bearish trend or market. The daily chart of ABT reveals that it has lost some grounds as it ended Wednesday with a -5.39% fall over the past 30 days.